- Home
- STGW vs IMNM Comparison
STGW vs IMNM Comparison
Compare STGW & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- IMNM
- Stock Information
- Founded
- STGW 1980
- IMNM 2006
- Country
- STGW United States
- IMNM United States
- Employees
- STGW N/A
- IMNM N/A
- Industry
- STGW
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- STGW
- IMNM Health Care
- Exchange
- STGW Nasdaq
- IMNM Nasdaq
- Market Cap
- STGW 662.6M
- IMNM 585.5M
- IPO Year
- STGW N/A
- IMNM 2020
- Fundamental
- Price
- STGW $6.63
- IMNM $10.17
- Analyst Decision
- STGW Strong Buy
- IMNM Strong Buy
- Analyst Count
- STGW 5
- IMNM 5
- Target Price
- STGW $8.50
- IMNM $28.60
- AVG Volume (30 Days)
- STGW 345.5K
- IMNM 881.8K
- Earning Date
- STGW 02-25-2025
- IMNM 11-13-2024
- Dividend Yield
- STGW N/A
- IMNM N/A
- EPS Growth
- STGW N/A
- IMNM N/A
- EPS
- STGW 0.00
- IMNM N/A
- Revenue
- STGW $2,707,403,000.00
- IMNM $10,129,000.00
- Revenue This Year
- STGW $13.05
- IMNM N/A
- Revenue Next Year
- STGW N/A
- IMNM N/A
- P/E Ratio
- STGW $2,390.91
- IMNM N/A
- Revenue Growth
- STGW 4.92
- IMNM N/A
- 52 Week Low
- STGW $4.88
- IMNM $8.97
- 52 Week High
- STGW $8.18
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- STGW 49.63
- IMNM 42.41
- Support Level
- STGW $5.81
- IMNM $9.24
- Resistance Level
- STGW $6.57
- IMNM $11.06
- Average True Range (ATR)
- STGW 0.23
- IMNM 0.73
- MACD
- STGW 0.05
- IMNM -0.03
- Stochastic Oscillator
- STGW 92.13
- IMNM 39.41
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; Communications Network and other. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.